1. Determination and pharmacokinetic study of Enasidenib in rat plasma by UPLC–MS/MS.
- Author
-
Pang, Ni-hong, Liu, Qian, Lu, Xiang-ran, Yang, Su-fen, Lin, Dong-dong, and Hu, Guo-xin
- Subjects
- *
ACUTE myeloid leukemia treatment , *DRUG therapy , *IMATINIB , *ELECTROSPRAY ionization mass spectrometry , *PHARMACOKINETICS , *LIQUID chromatography-mass spectrometry , *LABORATORY rats - Abstract
Enasidenib, an oral product for treating Acute Myeloid Leukemia, has been approved by FDA in Aug, 2017. In this study, we set up an ultra-performance liquid chromatography-mass spectrometry (UPLC-MS/MS) method for measuring Enasidenib and imatinib (internal standard, IS), simultaneously. Enasidenib and imatinib were separated on an ACQUITY UPLC BEH C 18 Column (2.1 mm × 50 mm, 1.7 μm, 132 Å). Mass detection was carried out by electrospray ionization in the position mode, and the multiple reaction monitoring transitions were m/z 474.23 → 456.17 and m/z 494.30 → 394.20 for Enasidenib and imatinib, respectively. Linearity (2 − 500 ng·mL −1 , R 2 > 0.999), precision and accuracy (RE < ± 15%), extraction recovery (≥ 96.69%), matrix effect (≥ 96.47%) and stability (RE < ± 10%) were validated which demonstrated the robustness of our method. This rapid, efficient and reliable UPLC-MS/MS method shows specificity and repeatability of Enasidenib in rat plasma and can be used in further pharmacokinetic studies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF